Announcement on Receipt of Arbitration Notice
Filed with SSE · · 3 pages · Chinese
Summary by 6ix AI
The arbitration has been accepted but the proceedings have not yet begun, with the company being the respondent in this case. The company is taking the matter seriously and will keep investors informed about any developments in the arbitration process.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Jiangsu Yahong Meditech Co., Ltd. on 6ix
Earlier from Jiangsu Yahong Meditech
- Announcement on Listing and Circulation of Partial Restricted Shares in Initial Public Offering
- Announcement on Adjustment of Key Technical Personnel
- Announcement on Vesting Results of the 3rd Vesting Period of Those Initially Granted and the 2nd Vesting Period of Those Reserved for Grant in 2022 Restricted Stock Incentive Plan and Listing of Stocks
- Announcement on Resolutions of the 2025 Annual General Meeting
- Announcement on Resignation of Securities Affairs Representative
Later from Jiangsu Yahong Meditech
- Announcement on Arbitration Progress and Submission of Counter‑claim in Arbitration
- Announcement on Voluntary Disclosure of the FDA Approval of the APL-2501 Clinical Trial Application
- Jiangsu Asieris Pharmaceuticals Co., Ltd.: Announcement on Voluntary Disclosure of the Approval of the Clinical Trial Application for APL-2501 by the National Medical Products Administration
- Jiangsu Asieris Pharmaceuticals Co., Ltd.: Announcement on Voluntary Disclosure of APLD-2304 Obtaining EU CE Certification
- Special Report on the Deposit and Actual Use of Raised Funds for the First Half of 2026
Follow Jiangsu Yahong Meditech into a list and get an email when it puts out news.
Follow Jiangsu Yahong Meditech